SecBot SecBot
PRESS-RELEASE ·Filed Sep 14, 2026

BNTX

BioNTech SE
BULLISH
Impact 7/10
Horizonmonths Processed2mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

The nearly doubled median OS is a strong efficacy signal for gotistobart in a difficult-to-treat population. Traders should watch for updates from the pivotal stage 2 of PRESERVE-003 and any regulatory interactions. Positive data could significantly de-risk the asset and support BioNTech's oncology pipeline beyond COVID.

DirectionBullish
Confidencehigh
Horizonmonths

gotistobart

● Neutral Named in this press release
Impact
Phase
Phase 3
Time to market
At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
Next catalyst
None dated

What to watchThe key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$98.86
T+0 close · Sep 14, 2026 · via day close
Latest settled
−3.05%
T+20 · $95.84 · next T+60 in 21d
Vs SPY
−5.32%
α at T+20
Latest observation
−9.98%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $98.86entry
  2. T+1 · 2mo ago −2.19%α −1.74% · $96.69
  3. T+5 · 8w ago −0.87%α −0.98% · $98.00
  4. T+20 · 5w ago −3.05%α −5.32% · $95.84
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech and OncoC4 announced positive median overall survival (OS) data from stage 1 of the PRESERVE-003 Phase 3 trial for gotistobart in squamous NSCLC patients who progressed on prior immunotherapy and chemotherapy. Gotistobart nearly doubled median OS to 18.5 months vs 10.0 months for docetaxel (HR: 0.56, p=0.0295), a statistically significant and clinically meaningful result. The data were presented at WCLC 2026 and support the ongoing pivotal stage 2 of the trial.

Key Facts

  • Gotistobart showed median OS of 18.5 months vs 10.0 months for docetaxel (HR: 0.56, p=0.0295)
  • Data from non-pivotal stage 1 of PRESERVE-003 Phase 3 trial in squamous NSCLC patients after prior immunotherapy and chemotherapy
  • Pivotal stage 2 of PRESERVE-003 is ongoing at >160 sites globally
  • Gotistobart received Fast Track Designation from FDA (2022) and Orphan Drug Designation for squamous NSCLC (2025)
  • Safety profile manageable: Grade ≥3 treatment-related AEs in 44.4% (gotistobart) vs 48.8% (docetaxel)

Financial Impact

Potential multi-billion dollar peak sales opportunity if approved in second-line squamous NSCLC, a large market with limited options

revenuepipeline value

Risk Factors

  • Stage 1 data is non-pivotal; pivotal stage 2 results are needed for registration
  • Competition from other CTLA-4 and novel immunotherapies in NSCLC
  • Regulatory approval not guaranteed; safety and manufacturing reviews remain

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
78% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3360734

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026